Amylin (Cagrilintide) (Cagrilintide)
buy in Ukraine
Amylin analog — a new pathway for appetite control
Long-acting amylin hormone analog. Cagrilintide is an investigational molecule developed by Novo Nordisk; Amilin by PeptoLabs is a third-party research-grade product (not manufactured by Novo Nordisk and not CagriSema). The best-studied GLP-1 combination is CagriSema (cagrilintide + semaglutide). 10/20 mg pens.
Manufacturer: PeptoLabs Amilin (10 mg or 20 mg pre-mixed pen). Standard CagriSema titration (Novo Nordisk Phase 3): weeks 1–4 — 0.25 mg/week; weeks 5–8 — 0.5 mg/week; weeks 9–12 — 1.0 mg/week; weeks 13–16 — 1.7 mg/week; from week 17 — maintenance 2.4 mg/week. Pen calculation: 16-week starter course ≈ 27 mg → 3 pens of 10 mg or 1.5 pens of 20 mg. Maintenance at 2.4 mg/week: 20 mg pen — for 8–9 weeks, 10 mg pen — for 4 weeks. Long-term course — minimum 6 months for significant weight loss. REDEFINE-1/2 clinical studies — 68 weeks. The best-studied GLP-1 combination is CagriSema (cagrilintide + semaglutide): −22.7% weight loss over 68 weeks (REDEFINE-1, NEJM 2025, trial-product estimand). There are currently no controlled human trials of cagrilintide combined with tirzepatide or retatrutide.
Free specialist consultation
Benefits
- ✓Separate from GLP-1 mechanism — an amylin appetite-control pathway (the only clinically proven combination is CagriSema)
- ✓–22.7% weight loss in CagriSema (REDEFINE-1, NEJM 2025, 68 weeks) — one of the highest published Phase 3 results
- ✓–10.8% in monotherapy over 26 weeks (Phase 2, Lancet 2021)
- ✓In T2D on metformin: –15.6% weight, –2.2% HbA1c combined with semaglutide
- ✓Does NOT cause hypoglycemia (unlike insulin and sulfonylureas)
- ✓Gradual 16-week titration — smooth buildup, minimal side effects
- ✓Convenient weekly dosing — half-life ~7 days
- ✓Glycemic control in T2D: HbA1c −1.8% (REDEFINE-2, CagriSema combination data); effect on cardiovascular outcomes has not been established
- ✓Alternative/addition for patients plateauing on GLP-1 monotherapy
Who may find it relevant
- ✔️Weight plateau on GLP-1 (Ozempic/Mounjaro) — the amylin pathway as a separate appetite-control mechanism; clinical efficacy of combinations beyond CagriSema has not been established
- ✔️Patients who don't tolerate high GLP-1 doses — lower dose + cagrilintide instead of dose increase
- ✔️T2D on metformin — better glycemic and weight control than semaglutide-mono
- ✔️Biohackers / advanced users interested in the amylin appetite-control mechanism
- ✔️Post-surgical weight maintenance (bariatric) — adjuvant against recidivism
- ✔️Those wanting SEPARATE appetite control mechanism without duplicating GLP-1
How to take
Standard 16-week titration (Novo Nordisk Phase 3 CagriSema):
• Weeks 1–4: 0.25 mg subcutaneous once weekly.
• Weeks 5–8: 0.5 mg subcutaneous once weekly.
• Weeks 9–12: 1.0 mg subcutaneous once weekly.
• Weeks 13–16: 1.7 mg subcutaneous once weekly.
• Week 17+: 2.4 mg subcutaneous once weekly (maintenance).
Maximum dose in clinical studies: 4.5 mg/week (Phase 2 mono); in CagriSema — 2.4 mg/week.
Administration: subcutaneous in abdomen, thigh or arm. One day per week — e.g., "Cagri-Sunday". Can inject any time of day regardless of meals. Rotate injection sites. PeptoLabs pen — programmable, set mg.
If a specialist prescribed a GLP-1 combination (DOZA practical protocol; the only clinically proven combination is CagriSema with semaglutide):
• Usually inject on different days (Mounjaro Monday, Cagri Friday) — to better assess tolerability.
• When combining with GLP-1, titration may be slower to avoid cumulative GI side effects.
• Combination start — only after stabilization on GLP-1 (2.4 mg or 5 mg).
Storage: 2–8°C (refrigerator). Do not freeze. Outside cold storage — no longer than 4 hours (during travel in thermal bag).
Before starting — mandatory DOZA specialist consultation (assessment of goals, risks, protocol).
Full description
Cagrilintide is a long-acting analog of human amylin hormone, developed by Novo Nordisk as a key component of the CagriSema project (cagrilintide + semaglutide). The molecule is a modified amylin with added fatty acid (like semaglutide), extending half-life from 12 minutes (native amylin) to ~7 days — convenient weekly dosing.
Amylin is the second hormone of pancreatic β-cells (alongside insulin), released in response to food intake. It regulates satiation through action on the area postrema (brain area outside blood-brain barrier) and nucleus tractus solitarius (NTS). This is a SEPARATE pathway from GLP-1 for appetite control — the mechanisms are theoretically complementary, but the only clinically proven combination is with semaglutide (CagriSema); there are no controlled trials with tirzepatide or retatrutide.
Clinical results:
• Phase 2 monotherapy (Lancet 2021, n=706, 26 weeks): –10.8% weight loss at 4.5 mg/week dose.
• REDEFINE-1 (Garvey et al., NEJM 2025, n=3417, 68 weeks): CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) → –22.7% weight loss (trial-product estimand; –20.4% treatment-policy). Semaglutide 2.4 mg mono → –16.1%, cagrilintide 2.4 mg mono → –11.8%.
• REDEFINE-2 (Davies et al., NEJM 2025, n=1206, T2D): CagriSema → –13.7% weight loss (treatment-policy; adherent –15.7%), –1.8% HbA1c — better result than semaglutide-mono.
• Phase 2 T2D on metformin: cagrilintide 1.2 mg + semaglutide 1.2 mg → –15.6% weight loss, –2.2% HbA1c.
Manufacturer: PeptoLabs Amilin (10 mg or 20 mg pre-mixed pen). Storage: 2–8°C, do not freeze. Product not approved by FDA/EMA/МОЗ of Ukraine. Phase 3 successfully completed; the CagriSema NDA was filed to the FDA on 18 Dec 2025, with a decision expected in Q4 2026. REDEFINE clinical data refer to the original Novo Nordisk molecule; Amilin (PeptoLabs) is a research-grade product. Available at DOZA as research-grade medication for patients not achieving goals on GLP-1 monotherapy.
Mechanism of action
Cagrilintide is modified amylin: natural 37 amino acid sequence + conjugated C20-fatty acid via linker (like semaglutide) → plasma albumin binding → half-life extension from 12 min to ~7 days → weekly dosing. Mechanism of action: 1) Activation of amylin receptors (AMY1, AMY2, AMY3 — heterodimers of calcitonin receptor with RAMP1/2/3) in area postrema and NTS → appetite suppression and enhanced satiation. 2) Slows gastric emptying (synergy with GLP-1 in CagriSema). 3) Suppresses postprandial glucagon secretion → ↓post-meal hyperglycemia. 4) Separate from GLP-1 receptor pathway → theoretically complementary mechanisms; the only clinically confirmed combination is CagriSema (cagrilintide + semaglutide). 5) Unlike pramlintide (short-acting amylin, FDA 2005) doesn't require 3-times daily dosing — weekly format improves compliance. 6) Does NOT cause hypoglycemia when used without insulin — amylin signaling is physiological.
Side effects & contraindications
Cagrilintide is well tolerated. Side effect profile similar to GLP-1 but milder (especially with proper 16-week titration).
Common (10–20%, mainly during titration start):
• Nausea — 15–25% at start, resolves within 5–7 days of adaptation.
• Decreased appetite — desired therapeutic effect.
• Constipation or diarrhea — 10–15%.
• Delayed gastric emptying, heaviness after meals — 8–12%.
Less common (3–5%):
• Injection site reaction (redness, itching) — mild, temporary.
• Headache — rare.
• Fatigue first 1–2 weeks.
• Cholelithiasis (gallstones) — like GLP-1, due to rapid weight loss.
Serious (rare):
• Severe gastroparesis — in patients with existing diabetic gastroparesis.
• Allergic reactions — rare.
• Theoretical risk of medullary thyroid cancer (MTC) — like GLP-1; studies ongoing.
Contraindications:
• Personal or family history of medullary thyroid cancer (MTC).
• Multiple endocrine neoplasia type 2 (MEN-2).
• Active diabetic gastroparesis.
• History of intestinal obstruction.
• Active pancreatitis.
• Severe gastroesophageal reflux with esophagitis.
• Pregnancy and lactation.
• Allergy to medication components.
• Severe renal insufficiency (eGFR <30) — limited data.
At DOZA before starting — history assessment and optional baseline labs (TSH, lipase, eGFR). Specialist consultation — mandatory.
Scientific research
📄Cagrilintide has been part of Novo Nordisk's active clinical program since 2018. Key studies: 1) Phase 1b mono (Diabetes Care 2021) — 0.16–4.5 mg/week × 26 weeks, dose-dependent weight loss up to –10.8%. 2) Phase 2 mono (Lau et al., Lancet 2021, n=706, 26 weeks) — up to –10.8%. 3) Phase 2 T2D + metformin — cagrilintide 1.2 + semaglutide 1.2 = –15.6% weight, –2.2% HbA1c (vs semaglutide 2.4 mono: –5.1% / –1.8%). 4) REDEFINE-1 (Garvey et al., NEJM 2025, n=3417, 68 weeks, without T2D) — CagriSema (cagrilintide 2.4 + semaglutide 2.4) → –20.4% weight (treatment-policy) / –22.7% (trial-product, adherent); semaglutide 2.4 mono → –16.1%, cagrilintide 2.4 mono → –11.8%, placebo → –2.3%. 5) REDEFINE-2 (Davies et al., NEJM 2025, n=1206, T2D) — CagriSema → –13.7% weight (treatment-policy; adherent –15.7%), –1.8% HbA1c. 6) Regulatory: CagriSema NDA filed to the FDA on 18 Dec 2025, decision expected in Q4 2026; cardiovascular-outcome trials ongoing. Cagrilintide mono is not in Phase 3 — Novo focuses on CagriSema. 7) FDA (statement of 15 Jun 2026): cagrilintide cannot be used in compounding under US federal law — it is not a component of any FDA-approved drug and has not been found safe and effective.
Frequently Asked Questions about Amylin (Cagrilintide)
Cagrilintide (Amilin 10 mg or 20 mg pre-mixed pen from PeptoLabs) can be ordered through DOZA with quality guarantee and 24/7 support. Delivery across Ukraine 1–2 days in thermal box (cold chain 2–8°C). 20 mg pen at standard maintenance dose 2.4 mg/week — lasts ~8–9 weeks. Before ordering — DOZA specialist consultation (protocol assessment: mono or combination with Mounjaro/Ozempic). Check exact price and pen quantity for course with consultant.
DOZA Specialist
Buy Amylin (Cagrilintide) in Ukraine — DOZA
Amylin (Cagrilintide) is available in Ukraine through DOZA online service. Amylin analog — a new pathway for appetite control. We ensure original quality, safe storage and delivery across Ukraine via Nova Poshta. Every order includes a free specialist consultation.
Price of Amylin (Cagrilintide) — 16 400 ₴. For detailed information about dosage, course and suitability, please consult a DOZA specialist.
Buy Amylin (Cagrilintide) with 1–2 day delivery across Ukraine. Cold chain 2–8°C. We respond 24/7.
